Viking Therapeutics price target raised to $116 from $46 at Oppenheimer

Oppenheimer raised the firm’s price target on Viking Therapeutics to $116 from $46 and keeps an Outperform rating on the shares. The positive topline results from the Phase 2 VENTURE trial of VK2735 are “the best-case scenario,” says the analyst, who believes Viking has multiple options to explore additional dosing regimens and further optimize the safety/efficacy profile and improve the patient experience given the “promising results.”